This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated ATP2A2 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-ATP2A2 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~114.8 kDa | |
| Gel | 8–10% (standard starting point) | |
| Positive control | Cerebellum (IHC candidate; verify WB) +4 more | |
| Negative control | Adipose tissue (IHC candidate; verify WB) |
| PTM | Phosphorylated | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 5 isoform(s) |
The M01176 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | HeLa cell lysate (catalog M01176) |
| Gel % | 8–10% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Wet/tank transfer; optimize duration (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | M01176; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
ATP2A2 is predicted at 114.8 kDa; isoforms could affect migration, but distinct bands and an empirical apparent mass are not demonstrated.
| Band near 114.8 kDa | Consistent with the predicted full-length ATP2A2 mass; identity needs confirmation |
| Several discrete bands | Could reflect annotated isoforms 1–5, although distinct migration is unverified |
| Weak band in whole-cell lysate | Recovery of this multi-pass membrane protein may be limited |
| Stronger band in an ER or SR membrane fraction | Consistent with ATP2A2 membrane localization; identity needs confirmation |
| Predicted full-length mass | Provides a 114.8 kDa reference, not a measured band position |
| Splice isoform 1 | Apparent size relative to the other isoforms is unknown |
| Splice isoform 2 | Could differ in size; its mass is not supplied |
| Splice isoform 3 | Could differ in size; its mass is not supplied |
| Splice isoform 4 | Could differ in size; its mass is not supplied |
| Splice isoform 5 | Could differ in size; its mass is not supplied |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Incomplete recovery of membrane-localized ATP2A2 is possible | Check membrane extraction and test an ER or SR membrane fraction |
| Band higher than expected | Apparent migration or band identity is uncertain | Check the size marker and confirm identity with an independent antibody or ATP2A2-depleted control |
| Band lower than expected | An isoform is possible, but no isoform size is supplied | Confirm identity and assess which ATP2A2 isoforms the sample expresses |
| Multiple bands | Five isoforms are annotated, but their separation on a blot is unverified | Compare isoform expression and validate bands with an independent antibody or ATP2A2-depleted control |
| Weak or no signal | Membrane extraction may yield little ATP2A2 | Check extraction and loading, then compare with a membrane-enriched sample |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Purkinje cells - cytoplasm/membrane | High | Protein (IHC) | HPA → |
| Heart muscle | cardiomyocytes | High | Protein (IHC) | HPA → |
| Skeletal muscle | myocytes | High | Protein (IHC) | HPA → |
| Bronchus | respiratory epithelial cells | Medium | Protein (IHC) | HPA → |
| Caudate | neuronal cells | Medium | Protein (IHC) | HPA → |
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | adipocytes | Not detected | Protein (IHC) | HPA → |
| Cervix | glandular cells | Not detected | Protein (IHC) | HPA → |
Deeper troubleshooting and optimisation questions for ATP2A2, answered from its protein features.
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
The catalog reports M01176, an anti-ATP2A2 (SERCA2) rabbit monoclonal antibody with reported human, mouse, and rat reactivity. Its Western blot image shows SERCA2 detection in HeLa cell lysate; the supplied evidence does not show mouse or rat samples.
Which to pick: M01176 is the only listed option. It has a Western blot image using HeLa cell lysate; check its reported reactivity against your sample species.